Monday, March 13, 2017 10:10:13 PM
http://ih.advfn.com/p.php?pid=nmona&article=74081598&symbol=VBIO
Item 1.01. Entry into a Material Definitive Agreement.
On March 9, 2017, Vitality Biopharma, Inc., a Nevada corporation (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company issued to the Purchasers an aggregate of 1,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of US$1.00 per share, for the aggregate purchase price of US$1,500,000.00 (the “Purchase Price”), which closed on March 9, 2017. The Securities Purchase Agreement contains customary representations, warranties, covenants and conditions for agreements of this type. The Company is not required to file a registration statement covering these securities.
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM